How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
BOTHELL, Wash., March 06, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention of migraine, will be presented at the upcoming 69th Annual American Academy of Neurology meeting on April 22-28, 2017 in Boston.
- Platform presentation: Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine
Session: S52, Headache: Clinical Trials and Disease Burden
Date: Friday, April 28, 2017
Presenter: Dr. David Dodick
Time: 1:24 p.m.
Location: Boston Convention and Exhibition Center
- Poster presentation: Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine
Poster: #155
Date: Monday, April 24
Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
Location: Boston Convention and Exhibition Center, Poster Session II
- Poster presentation: 75% Responder Rates Provide Improvement in HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of ALD403, or Placebo
Poster: #165
Date: Monday, April 24
Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
Location: Boston Convention and Exhibition Center, Poster Session II
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals Inc. (425) 408-8032 [email protected]
